INTERIM REPORT JANUARY – JUNE 2005

• Turnover during the period amounted to SEK 437.5 (401.1) million, an increase of 9 percent. • Operating income amounted to SEK 21.4 (164.1) million. Adjusted for revenues and expenses of a one-time nature operating income amounted to SEK 31.7 (33.4) million. • Net income after tax amounted to SEK 23.6 (166.8) million. • Earnings per share for the period were SEK 0.95 (6.72). • Oxalate project obtains external financing. • Continued strong growth, 54 percent, for the Hospital Healthcare product area. Queries should be addressed to: Erika Kjellberg Eriksson, Vice President and CFO, tel: +46 (0) 70-974 90 20 Anne Rhenman, Director Investor Relations, tel:+46 (0) 70-974 90 15